The Pharmacogenomics Journal, Published online: 01 October 2026; doi:10.1038/s41397-026-00430-4 The role of pharmacogenomics in epilepsy treatment: advancements in personalized medicine
Najmeh Ahangari, Mohammad Doosti, Mojtaba Safi, Narges Hashemi, Shima Imannezhad, Bita Barazandeh et al. The role of pharmacogenomics in epilepsy treatment: advancements in personalized medicine. // The Pharmacogenomics Journal. – 2026. – DOI: 10.1038/s41397-026-00430-4. – URL: https://www.nature.com/articles/s41397-026-00430-4
Najmeh Ahangari, Mohammad Doosti, Mojtaba Safi, Narges Hashemi, Shima Imannezhad, Bita Barazandeh, Ehsan Ghayoor Karimiani, & Mehran Beiraghi Toosi (2026). The role of pharmacogenomics in epilepsy treatment: advancements in personalized medicine. The Pharmacogenomics Journal. https://doi.org/10.1038/s41397-026-00430-4
Najmeh Ahangari, et al. “The role of pharmacogenomics in epilepsy treatment: advancements in personalized medicine.” The Pharmacogenomics Journal, 2026. doi:10.1038/s41397-026-00430-4.
@article{Ahangari2026,
title = {The role of pharmacogenomics in epilepsy treatment: advancements in personalized medicine},
author = {Ahangari, Najmeh and Doosti, Mohammad and Safi, Mojtaba and Hashemi, Narges and Imannezhad, Shima and Barazandeh, Bita and Karimiani, Ehsan Ghayoor and Toosi, Mehran Beiraghi},
journal = {The Pharmacogenomics Journal},
year = {2026},
doi = {10.1038/s41397-026-00430-4},
url = {https://www.nature.com/articles/s41397-026-00430-4}
}
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05030-x Comment on: ‘Association of accelerometer-monitored physical activity with incident cataract: epidemiological and genetic evidence’
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05032-9 NAION during incretin-based therapy: an optic nerve head still adapted to hypertension
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05016-9 Comparing refractive errors in CACNA1F and CABP4 -associated disease in a UK cohort
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05018-7 Comment on: ‘Determinants of regression kinetics in observed stage 3 retinopathy of prematurity without plus disease’